CSL Behring submits MAA to EMA for rVIII-SingleChain for patients with hemophilia A
In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints. Hemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII; nearly all affected patients